CD274 and neoplasm: KD033 anti-tumor activity reproduced the previously reported KD033-surrogate efficacy in syngeneic murine models: a single injection of KD033 was more efficacious than the repeat treatment of anti-PD-L1, and KD033 was efficacious in both hPDL1+ and hPDL1- MC38 tumors.